albumin-bound docetaxel + bevacizumab

Albumin-bound docetaxel + bevacizumab is a **combination therapy** composed of a nanoparticle formulation of docetaxel bound to albumin and the monoclonal antibody bevacizumab. - **Albumin-bound docetaxel** is a chemotherapeutic agent utilizing albumin nanoparticles as a carrier for docetaxel, allowing improved solubility and drug delivery, similar in concept to the commercial paclitaxel formulation (nab-paclitaxel). Docetaxel is a small molecule **antineoplastic agent** and acts as a microtubule inhibitor, stabilizing the microtubule assembly during mitosis, thereby preventing cell division[2]. - **Bevacizumab** is a recombinant humanized monoclonal antibody targeting **vascular endothelial growth factor (VEGF)**, used to inhibit angiogenesis in cancer by blocking VEGF signaling necessary for tumor blood vessel growth[1]. This combination is primarily studied and used in cancers including advanced nonsquamous non-small cell lung cancer and is explored in other solid tumors. The rationale is to combine cytotoxic and antiangiogenic mechanisms for enhanced efficacy.

Other names

albumin-bound docetaxel and bevacizumabnanoparticle albumin-bound docetaxel + bevacizumab